Brilaroxazine
- Generic Name
- Brilaroxazine
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25Cl2N3O3
- CAS Number
- 1239729-06-6
- Unique Ingredient Identifier
- X8L60BA01I
- Background
Brilaroxazine (RP5063) is an investigational atypical antipsychotic which is under development by Reviva Pharmaceuticals for the treatment of schizophrenia and schizoaffective disorder. Reviva Pharmaceuticals also intends to investigate RP5063 for the treatment of bipolar disorder, major depressive disorder, psychosis/agitation associated with Alzheimer's disease, Parkinson's disease psychosis, attention deficit hyperactivity disorder (ADD/ADHD), and autism. As of May 2015, it is in phase III clinical trials for schizophrenia.
- Indication
Investigated for the treatment of schizophrenia and schizoaffective disorder.
- Associated Conditions
- -
- Associated Therapies
- -
5 Schizophrenia Candidates Chasing BMS' KarXT
Bristol Myers Squibb awaits FDA decision on KarXT, a novel schizophrenia treatment potentially representing the first new approach in decades. KarXT, acquired via $14 billion deal with Karuna Therapeutics, targets M1 and M4 muscarinic receptors, offering efficacy without antipsychotic side effects. Other companies, including Neurocrine Biosciences, AbbVie, Reviva Pharmaceuticals, Boehringer Ingelheim, and Alto Neuroscience, are also developing schizophrenia treatments, focusing on various mechanisms to address positive, negative, and cognitive symptoms.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath